SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-135616"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-135616" > Cyclin B is an immu...

Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer

Koliadi, Anthoula, (författare)
Uppsala universitet, Enheten för onkologi
Nilsson, Cecilia, (författare)
Uppsala universitet, Institutionen för onkologi, radiologi och klinisk immunologi, Uppsala universitet, Centrum för klinisk forskning, Västerås
Holmqvist, Marit, (författare)
Uppsala-Örebro Regional Oncologic Centre, Uppsala, Sweden
visa fler...
Holmberg, Lars, (författare)
Uppsala universitet, Endokrinkirurgi
de la Torre, Manuel, (författare)
Uppsala universitet, Institutionen för genetik och patologi
Wärnberg, Fredrik, (författare)
Uppsala universitet, Endokrinkirurgi
Fjällskog, Marie-Louise, (författare)
Uppsala universitet, Enheten för onkologi
visa färre...
2010
Engelska.
Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 49:6, s. 816-820
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • <p>Patients with low-risk node negative breast cancer have an excellent prognosis with 5% breast cancer mortality at 10 years. However, prognostic factors are needed to identify poor prognostic patients who might benefit from adjuvant systemic therapy. Proliferation has been identified as the most important component of gene expression profiles. Cyclin B is a proliferative marker easily assessed by immunohistochemistry. We wanted to examine cyclin B as a prognostic factor in low-risk breast cancer patients. Patients and methods. Using an experimental study design, we compared women dying early from their breast cancer (n=17) with women free from relapse more than eight years after initial diagnosis (n=24). All women had stage I, node negative and hormone receptor positive disease. None had received adjuvant chemotherapy. Tumor samples were immunostained for cyclin B using commercial antibodies. Results. The mean percentage of cyclin B (12%) was significantly higher (p=0.001) in women dying from their breast cancer compared with women free from relapse ( 5%). High cyclin B (&gt;= 9%) identified 11/17 patients dying from breast cancer and low cyclin B identified 22/24 patients free from relapse. The sensitivity and specificity of cyclin B was 65% and 92%, respectively. Discussion. We found that low-risk node negative patients with high expression of cylin B had a significantly worse outcome than patients with low expression of cyclin B. Cyclin B could separate patients with poor survival from those with good survival with 80% accuracy. We suggest that cyclin B might be a potent prognostic factor in this low-risk patient group.</p>

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy